Results 181 to 190 of about 5,170 (209)

Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells.

The Journal of Pharmacology and Experimental Therapeutics, 1995
Five subtypes of muscarinic acetylcholine receptors (m1-m5) have been expressed in insect cells (Spodoptera frugiperda, Sf9) using the baculovirus system. Up to 6 nmol of muscarinic acetylcholine receptors were produced by 1 liter culture; 0.3 to 0.6 (human m1), 3 to 6 (human m2), 2 to 4 (rat m3), 1 to 2 (rat m4) and 0.5 to 1 (human m5) nmol ...
Guanzhong Dong, Kimihiko Kameyama, Ago Rinken, Tatsuya Haga   +3 more
openalex   +3 more sources

Muscarinic M5 receptors trigger acetylcholine‐induced Ca²⁺ signals and nitric oxide release in human brain microvascular endothelial cells

Journal of Cellular Physiology, 2018
AbstractBasal forebrain neurons control cerebral blood flow (CBF) by releasing acetylcholine (Ach), which binds to endothelial muscarinic receptors to induce nitric (NO) release and vasodilation in intraparenchymal arterioles. Nevertheless, the mechanism whereby Ach stimulates human brain microvascular endothelial cells to produce NO is still unknown ...
Estella Zuccolo, Umberto Laforenza, Sharon Negri, Laura Botta, Roberto Berra‐Romani, Pawan Faris, Giorgia Scarpellino, Greta Forcaia, Giorgia Pellavio, Giulio Sancini, Francesco Moccia   +10 more
openalex   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Cloning of the rat m3, m4 and m5 muscarinic acetylcholine receptor genes by the Polymerase Chain Reaction (PCR) and the pharmacological characterization of the expressed genes

Life Sciences, 1992
The coding sequence of the rat m3, m4 and m5 subtypes of muscarinic acetylcholine receptor (mAChR) genes was amplified by the polymerase chain reaction (PCR), cloned, and expressed in the murine fibroblast (B82) cell line. Sequencing of the cloned genes revealed some nucleotide differences when compared with the DNA sequence published in the literature.
K, Kashihara, E V, Varga, S L, Waite, W R, Roeske, H I, Yamamura   +4 more
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly